GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corcept Therapeutics Inc (NAS:CORT) » Definitions » Accounts Receivable

Corcept Therapeutics (Corcept Therapeutics) Accounts Receivable : $41.1 Mil (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Corcept Therapeutics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Corcept Therapeutics's accounts receivables for the quarter that ended in Dec. 2023 was $41.1 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Corcept Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 27.71.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Corcept Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $2.79.


Corcept Therapeutics Accounts Receivable Historical Data

The historical data trend for Corcept Therapeutics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corcept Therapeutics Accounts Receivable Chart

Corcept Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.93 26.20 27.63 31.06 41.12

Corcept Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.06 32.56 32.55 34.63 41.12

Corcept Therapeutics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Corcept Therapeutics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Corcept Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=41.123/135.405*91
=27.71

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Corcept Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Corcept Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(368.221+0.75 * 41.123+0.5 * 7.73-114.812
-0-0)/103.405
=2.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Corcept Therapeutics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Corcept Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Corcept Therapeutics (Corcept Therapeutics) Business Description

Traded in Other Exchanges
Address
149 Commonwealth Drive, Menlo Park, CA, USA, 94025
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Executives
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
William Guyer officer: Chief Development Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gary Charles Robb officer: CHIEF FINANCIAL OFFICER C/O 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph Douglas Lyon officer: Chief Accounting Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Sean Maduck officer: See Remarks C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
David L Mahoney director SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
Hazel Hunt officer: Chief Scientific Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph K Belanoff director, officer: CHIEF EXECUTIVE OFFICER 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Baker G Leonard Jr director, 10 percent owner 755 PAGE MILL ROAD, SUITE A-200, PALO ALTO CA 94304-1005
Joshua M. Murray director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Atabak Mokari officer: Chief Financial Officer 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Gillian Cannon director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gregg H Alton director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Kimberly Park director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Andreas Grauer officer: Chief Medical Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025